

Pharmacy Drug Policy Checklist

POLICY NAME	Sabril (vigabatrin)	POLICY #	2376P

Criteria

Crit	eria for Coverage for Infantile Spasms
	1.1 Documented diagnosis of Infantile Spasms
	1.2 Used as monotherapy in pediatric patients for whom the potential benefits outweigh the potential risk of vision loss
	1.3 Age 1 month to 2 years
	1.4 Coverage of branded products require documented allergic reaction to generic vigabatrin
	1.5 Approval Time
Crit	eria for Coverage of Complex Partial Seizures
	2.1 Documented diagnosis of Complex Partial Seizures
	2.2 Member is 16 years of age
	2.3 Used as adjunctive therapy and CPS is refractory to other antiepileptic agents, such as
	levetiracetam, carbamazepine, zonisamide, or phenytoin
	levetiracetam, carbamazepine, zonisamide, or phenytoin 2.4 Inadequate response to at least 2 alternative treatments for CPS, such as divalproex or valproic acid
	2.4 Inadequate response to at least 2 alternative treatments for CPS, such as divalproex or
	2.4 Inadequate response to at least 2 alternative treatments for CPS, such as divalproex or valproic acid
	 2.4 Inadequate response to at least 2 alternative treatments for CPS, such as divalproex or valproic acid 2.5 Coverage of branded products require documented allergic reaction to generic vigabatrin